文献速递主动脉疾病

系统综述:血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂处方与腹主动脉瘤生长及事件的关联

Systematic Review Examining the Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Prescription and Abdominal Aortic Aneurysm Growth and Events.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2024-03-25

该系统综述与Meta分析检索5个数据库至2024年1月4日,纳入11项研究共58022例患者,评估ACEi或ARB处方与腹主动脉瘤生长、修复及破裂的关联。ACEi处方与AAA生长无显著关联,但与AAA破裂风险降低显著相关(OR 0.87),所有证据的GRADE确定性均为极低。

要点

  • ACEi处方与AAA生长无显著关联(SMD 0.01 mm/年,95%CI -0.26至0.28)。
  • ACEi处方与AAA破裂风险显著降低相关(OR 0.87,95%CI 0.81至0.93)。
  • ARB处方与AAA生长或AAA相关事件风险均无显著关联。

核心结论

  • ACEi或ARB处方与AAA生长无关联,但ACEi处方与AAA破裂和AAA相关事件风险降低相关,证据确定性极低。

研究设计与样本

  • 系统综述与Meta分析,检索MEDLINE、Embase、Scopus、Web of Science和Cochrane Library从建库至2024年1月4日,无语言限制。
  • 纳入报告ACEi或ARB处方与AAA生长、修复或破裂关联的随机对照试验和观察性研究。
  • 共纳入11项研究(2项RCT、8项观察性研究、1项来自7个人群个体患者数据的Meta分析),涉及58022例患者。
  • 使用随机效应模型进行Meta分析,采用GRADE评估证据确定性。

主要发现

  • ACEi处方与AAA生长无统计学显著降低(标准均数差0.01 mm/年,95%CI -0.26至0.28;p=0.93;I²=98%)。
  • ACEi处方与AAA修复无统计学显著关联(OR 0.73,95%CI 0.50至1.09;p=0.65;I²=61%)。
  • ACEi处方与AAA破裂风险显著降低相关(OR 0.87,95%CI 0.81至0.93;p<0.001;I²=26%)。
  • ACEi处方与AAA相关事件风险显著降低相关(OR 0.82,95%CI 0.72至0.95;p=0.006;I²=80%)。
  • ARB处方与AAA生长显著降低或AAA相关事件风险降低均无显著关联。

关键数值与推荐

  • 主要结局为AAA生长,次要结局为AAA破裂、AAA修复和AAA相关事件(破裂与修复合并)。
  • 2项RCT偏倚风险低;观察性研究中1项低、7项中等、1项高偏倚风险。
  • 所有发现的GRADE证据确定性均为极低。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 所有发现的GRADE证据确定性均为极低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Whether angiotensin II blockade is an effective medical treatment for abdominal aortic aneurysms (AAAs) has not been established. This systematic review and meta-analysis aimed to determine the association between angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) prescription and AAA growth and events. DATA SOURCES: MEDLINE, Embase, Scopus, Web of Science, and the Cochrane Library databases were searched from their inception to 4 January 2024, with no language restrictions. REVIEW METHODS: The five databases were searched for randomised controlled trials (RCTs) and observational studies reporting the association between ACEi or ARB prescription and AAA growth, repair, or rupture. The primary outcome was AAA growth, with secondary outcomes of AAA rupture, AAA repair, and AAA related events (rupture and repair combined). Risk of bias was assessed using the Risk of Bias 2 tool for RCTs and with a modified Newcastle-Ottawa scale for observational studies. Certainty of evidence was assessed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE). Random effects models were used for meta-analyses. RESULTS: Eleven studies (two RCTs, eight observational studies, and one meta-analysis of individual patient data from seven populations) involving 58 022 patients were included. ACEi prescription was not associated with a statistically significant reduction in AAA growth (standard mean difference 0.01 mm/year, 95% confidence interval [CI] -0.26 - 0.28; p = .93; I2 = 98%) or AAA repair (odds ratio [OR] 0.73, 95% CI 0.50 - 1.09; p = .65; I2 = 61%), but was associated with a statistically significantly lower risk of AAA rupture (OR 0.87, 95% CI 0.81 - 0.93; p < .001; I2 = 26%) and AAA related events (OR 0.82, 95% CI 0.72 - 0.95; p = .006; I2 = 80%). ARB prescription was not associated with significantly reduced AAA growth or a lower risk of AAA related events. The two RCTs had a low risk of bias, with one observational study having low, seven moderate, and one high risk of bias. All of the findings had a very low certainty of evidence based on the GRADE analysis. CONCLUSION: There was no association between ACEi or ARB prescription and AAA growth, but ACEi prescription was associated with a reduced risk of AAA rupture and AAA related events with very low certainty of evidence.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Tian K, Thanigaimani S, Gibson K, et al. Systematic Review Examining the Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Prescription and Abdominal Aortic Aneurysm Growth and Events. Eur J Vasc Endovasc Surg. 2024. PMID: 38537880. doi:10.1016/j.ejvs.2024.03.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。